- Conditions
- Hutchinson-Gilford Progeria Syndrome
- Interventions
- Progerinin, Lonafarnib
- Drug
- Lead sponsor
- PRG Science & Technology Co., Ltd.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 11,389
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatic Impairment, Normal Hepatic Function
- Interventions
- Esketamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Valproic Acid and Levocarnitine, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more
- Conditions
- Antineutrophil Cytoplasmic Antibody Associated Vasculitis
- Interventions
- STSA-1002 subcutaneous injection
- Drug
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Industry
- Eligibility
- 21 Years to 57 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Anemia, Sickle Cell
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Radiation Dermatitis
- Interventions
- StrataXRT, Calendula, Aquaphor
- Device · Drug
- Lead sponsor
- Stratpharma AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- None (Observational Study)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 40
- States / cities
- Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ofatunumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- HIV Infection
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- IGN002
- Biological
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Pittsburgh, Pennsylvania
- Conditions
- Parkinson's Disease
- Interventions
- No intervention.
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Not listed
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Graft Versus Host Disease
- Interventions
- MSCTC-0010 Dose Escalation
- Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Healthy Participants
- Interventions
- AZD8965, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Peripheral Arterial Disease
- Interventions
- Atherectomy Catheter
- Device
- Lead sponsor
- Avinger, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 12
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • San Diego, California + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Part 1: Daratumumab, Part 2: Daratumumab, Methylprednisolone, Dexamethasone
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Concussion, Mild, Neurocognitive Dysfunction
- Interventions
- Not listed
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Treatment Resistant Depression
- Interventions
- ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
- Drug
- Lead sponsor
- Alar Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- ClinOne, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Greenwood Village, Colorado
- Conditions
- Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
- Interventions
- PQ203
- Drug
- Lead sponsor
- ProteinQure Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Houston, Texas • San Antonio, Texas • West Valley City, Utah
- Conditions
- Graft-vs-Host Disease, GVHD
- Interventions
- Brentuximab Vedotin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
- Interventions
- BH-30236, Venetoclax
- Drug
- Lead sponsor
- BlossomHill Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Cancer of the Cervix, Cervical Neoplasms
- Interventions
- Boost radiation
- Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Predictive Cancer Model
- Interventions
- Liver Risk Computation Model (LIRIC), Liver Risk Computation Model (LIRIC)_cirrhosis, Liver Risk Computation Model (LIRIC)_no_cirrhosis
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 6,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts